Betamethasone

證據等級: L5

預測適應症: 10 個

Betamethasone: From Inflammatory Skin Conditions to Alopecia Areata

One-Sentence Summary

Betamethasone is a potent synthetic glucocorticoid widely used clinically for inflammatory, allergic, and autoimmune conditions — though no Health Canada DINs were identified in this dataset. The TxGNN model predicts it may be effective for Alopecia Areata (AA), with 7 clinical trials and 20 publications currently supporting this direction; notably, betamethasone is already recognized in international clinical practice as a standard treatment for AA, making this a strong evidence-backed prediction rather than a novel hypothesis.

Quick Overview

Item	Content
Original Indication	Inflammatory and autoimmune conditions (synthetic glucocorticoid; no DIN identified in this dataset)
Predicted New Indication	Alopecia Areata
TxGNN Prediction Score	99.97%
Evidence Level	L2
Canada Market Status	Not marketed (0 DINs on file)
Number of DINs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Betamethasone is a synthetic fluorinated glucocorticoid belonging to the same pharmacological class as prednisolone and dexamethasone, but with significantly greater potency (approximately 25–40 times that of prednisolone on a weight basis). Although detailed MOA data was not captured in this Evidence Pack, its mechanism is well-established in the pharmacological literature: betamethasone binds the intracellular glucocorticoid receptor alpha (GR-α), translocates to the nucleus, and suppresses the NF-κB transcription pathway. This leads to downregulation of key pro-inflammatory cytokines — including IL-1β, IL-6, and IFN-γ — and reduces lymphocyte trafficking and activation at sites of inflammation.

Alopecia areata is a T cell–mediated autoimmune disease in which CD8+ cytotoxic T cells aberrantly attack hair follicles at the bulge region, collapsing the normal state of immune privilege that healthy follicles maintain. This targeted immune attack causes non-scarring, often patchy hair loss. Betamethasone’s broad immunosuppressive action directly addresses this pathophysiology: by suppressing perifollicular T cell infiltration and restoring the follicular immune microenvironment, it can halt the autoimmune assault and allow hair regrowth. This rationale is mechanistically sound and mirrors the approach used with other corticosteroids (e.g., triamcinolone, methylprednisolone) that have an established role in AA.

Clinical application of betamethasone for AA spans multiple routes — topical formulations (cream, lotion), intralesional injection, and oral mini-pulse regimens — each targeting different severities of disease. The breadth of clinical trial activity and published literature reviewed below confirms that this is not a speculative repurposing: betamethasone is actively studied and used in this indication globally, and the TxGNN model’s high-confidence prediction aligns with real-world clinical evidence.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06786689	Phase 2	Completed	60	Head-to-head RCT comparing oral betamethasone mini-pulse (BOMP) vs. weekly azathioprine pulse in moderate-to-severe AA; provides direct efficacy and safety data for oral betamethasone in this indication
NCT02350023	Phase 4	Completed	50	Randomized comparison of topical betamethasone vs. topical latanoprost for localized AA; betamethasone serves as the active standard-of-care arm, confirming its real-world reference status
NCT03535233	Phase 4	Completed	40	RCT comparing combined topical 5% minoxidil + potent topical corticosteroid (including betamethasone) vs. intralesional triamcinolone injection in AA; supports betamethasone in combination topical regimens
NCT05803070	N/A	Unknown	59	Comparison of topical cetirizine 1% vs. topical betamethasone valerate 0.1% in localized AA; betamethasone as the active control arm; status unknown limits interpretability
NCT06087796	Phase 1	Unknown	60	Three-arm trial evaluating topical pentoxifylline 2% and metformin 10% gels vs. topical betamethasone valerate 0.1% cream in patchy AA; betamethasone serves as benchmark comparator
NCT01111981	Phase 4	Unknown	30	Safety/efficacy study of clobetasol propionate 0.05% foam in central centrifugal cicatricial alopecia (CCCA); different drug and different alopecia subtype — limited direct relevance
NCT04207931	Phase 4	Recruiting	250	Multicenter prospective study of CCCA treatment outcomes; betamethasone may be one comparator but the indication (CCCA vs. AA) and status (still recruiting) limit applicability

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37870096	2023	Network Meta-Analysis	Cochrane Database of Systematic Reviews	Cochrane NMA synthesizing evidence across immunosuppressants, hair growth stimulants, and contact immunotherapy for AA; highest-quality synthesis of the treatment landscape including corticosteroids
39393548	2025	RCT	Journal of the American Academy of Dermatology	Microneedle-assisted transdermal delivery of compound betamethasone in AA; demonstrates improved delivery and efficacy vs. standard injection, addressing the pain barrier of intralesional therapy
34400956	2021	RCT	Iranian Journal of Pharmaceutical Research	Double-blind, placebo-controlled RCT comparing oral betamethasone pulse (3 mg weekly), methotrexate (15 mg weekly), and combination in severe AA (n=36); direct evidence for oral betamethasone efficacy
40519428	2025	Clinical Study	Cureus	Prospective study assessing efficacy, safety, and tolerability of oral betamethasone mini-pulses in moderate-to-severe AA; intermittent dosing shown as promising alternative to continuous systemic steroids
38623137	2024	Comparative Study	Cureus	Head-to-head comparison of topical betamethasone dipropionate vs. topical minoxidil in AA patients; evaluates relative efficacy of the two most commonly used topical agents
37992355	2023	Review	Dermatology Practical & Conceptual	Comprehensive review of corticosteroid pulse therapy (including betamethasone) for AA: efficacy, relapse rates, side effects, and prognostic factors across different pulse regimens
36114868	2023	Comparative RCT	Archives of Dermatological Research	RCT of fractional CO₂ laser alone vs. combined with topical betamethasone valerate in AA (n=30); supports betamethasone as additive component in laser-based combination strategies
36257912	2022	Comparative RCT	Dermatologic Therapy	Six-arm blinded RCT comparing latanoprost, minoxidil, betamethasone, and combinations (18 patients per group) in AA; directly evaluates betamethasone efficacy and satisfaction vs. alternatives
32594786	2022	RCT	Journal of Dermatological Treatment	Within-patient randomized controlled trial comparing intralesional betamethasone vs. triamcinolone acetonide in localized AA; establishes comparative effectiveness data specific to intralesional betamethasone
37765130	2023	Translational/Experimental	Pharmaceuticals (Basel)	Development of polymeric and lipid nanoparticles co-entrapping betamethasone and minoxidil for follicle-targeted topical delivery in AA; supports rational formulation development for reduced systemic exposure

Safety Considerations

Detailed safety warnings and contraindications specific to betamethasone were not captured in this Evidence Pack’s regulatory dataset. Based on the available clinical trial data, the following considerations are relevant to the AA indication:

Route-specific risks: Oral and systemic corticosteroid use carries well-recognized risks including HPA axis suppression, hyperglycemia, weight gain, hypertension, osteoporosis, and immunosuppression — especially with prolonged use. The oral mini-pulse regimen (e.g., 3 mg once weekly) was specifically designed to minimize these effects compared to daily systemic dosing.
Topical/intralesional risks: Local skin atrophy, telangiectasia, and adrenal suppression with extensive topical application; post-injection subcutaneous atrophy with intralesional use.
Infection risk: Immunosuppression from systemic betamethasone may increase susceptibility to bacterial, fungal, and viral infections.

Please refer to the product monograph for complete warnings, contraindications, and drug interaction information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The evidence base for betamethasone in alopecia areata is substantial and well-established: multiple completed Phase 2/4 RCTs directly testing betamethasone (both topical and oral mini-pulse formulations), a 2023 Cochrane network meta-analysis, and 20 publications spanning RCTs, reviews, and comparative studies collectively support an L2 evidence level. This is not speculative repurposing — betamethasone is a recognized clinical option for AA internationally, and the TxGNN model’s 99.97% prediction score reflects this strong pharmacological and clinical alignment.

To proceed, the following is needed:

Health Canada DIN status clarification: This Evidence Pack shows zero DINs on file; betamethasone products may be marketed under compound formulations or via individual DINs not captured here. A targeted Health Canada Drug Product Database query is recommended before drawing regulatory conclusions.
Formal package monograph review: TFDA/Health Canada product monograph warnings, contraindications, and drug-drug interactions must be retrieved and assessed before entering a formal safety evaluation (DG001 and DG002 data gaps should be resolved).
Route-of-administration stratification: A structured benefit-risk assessment should differentiate between topical, intralesional, and oral mini-pulse routes, as the risk profiles differ substantially — topical use is generally low-risk while systemic use requires monitoring protocols.
Population-specific monitoring plan: Define CBC, fasting glucose, blood pressure, and bone density monitoring schedules appropriate to the intended use duration and patient population (adults vs. pediatric, localized vs. severe AA).
Comparison with newer AA therapies: Evaluate betamethasone’s positioning relative to approved JAK inhibitors (e.g., baricitinib, ritlecitinib) which represent a newer standard for moderate-to-severe AA, particularly for patients where corticosteroid use is contraindicated or has failed.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.